Oral News and Research

RSS

Pain, itching associated with shingles may be due to virus causing "short circuit" in nerve cells

The pain and itching associated with shingles and herpes may be due to the virus causing a "short circuit" in the nerve cells that reach the skin, Princeton researchers have found.

11 Sep 2013

Researchers study potential role of two risk factors in preeclampsia

Although preeclampsia occurs in about 3 percent of pregnancies, it's still unforeseen in many cases. A report of new research, now in press at the Journal of Reproductive Immunology, documents how two distinct risk factors combine to affect the odds that a first-time mother could develop the sometimes life-threatening pregnancy complication.

11 Sep 2013

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Boehringer Ingelheim today announced the completion of patient enrolment for a Phase IIa clinical trial investigating a new interferon-free, all-oral, direct-acting antiviral combination treatment for patients with genotype-1a chronic hepatitis C virus infection.

10 Sep 2013

Relmada Therapeutics reports positive results from pivotal pharmacokinetic study of LevoCap ER

Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.

10 Sep 2013

People with severe asthma are less likely to respond to treatment

Barcelona, Spain: People with severe asthma, who are often described as 'steroid-dependent', are actually less likely to respond to the treatment they depend on, when compared to people with mild asthma.

10 Sep 2013

Amino acid arginine improves treatment for type 2 diabetes

More than 371 million people worldwide suffer from diabetes, of whom 90% are affected by lifestyle-related diabetes mellitus type 2 (type 2 diabetes).

10 Sep 2013

New drug delivery system using NDs allows for direct application of chemotherapy to brain tumors

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a new drug delivery system using nanodiamonds (NDs) that allows for direct application of chemotherapy to brain tumors with fewer harmful side effects and better cancer-killing efficiency than existing treatments.

10 Sep 2013

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.

9 Sep 2013

Amendments to oral cancer bill would increase co-pay for oral cancer treatment, says NPAF

Citing the hardships certain to be faced by a population of California cancer patients on strained incomes, the National Patient Advocate Foundation (NPAF), a national non-profit organization providing the patient voice for legislative reform at the state and federal levels, pulled its support for AB 219 following amendments passed in the California state senate yesterday that would prohibitively increase the co-pay for oral cancer treatment.

7 Sep 2013

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

PharmAthene, Inc. announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were presented in two separate oral presentations at the 2013 Bacillus – ACT international anthrax conference in Victoria, British Columbia, Canada.

7 Sep 2013

D&A PHARMA to present 3 clinical studies for ALCOVER in 14th Congress of ESBRA at Warsaw

D&A PHARMA, a leading company in the Addiction therapeutic area, announces today its strong participation in the 14th Congress of European Company of Biomedical Search on the Alcoholism (ESBRA), which will be held in Warsaw from September 8th to 11th.

7 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

Apoptosis can reactivate latent herpesviruses in dying cell

Researchers have found that apoptosis, a natural process of programmed cell death, can reactivate latent herpesviruses in the dying cell. The results of their research, which could have broad clinical significance since many cancer chemotherapies cause apoptosis, was published ahead of print in the Journal of Virology.

6 Sep 2013

Rigel Cuts 30 Jobs, Refocuses On Three Clinical Programs

...

5 Sep 2013

Survey shows most Americans are not prepared to deal with dental emergency

Although 72 percent of Americans have fillings, caps or crowns, most are not prepared to deal with a dental emergency, according to a survey conducted by Majestic Drug Company, a leading provider of oral care products.

5 Sep 2013

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

Experimental agent fails to increase HDL levels, reveals new study

The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

5 Sep 2013

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

5 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Oral News and Research

Pain, itching associated with shingles may be due to virus causing "short circuit" in nerve cells

Researchers study potential role of two risk factors in preeclampsia

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Relmada Therapeutics reports positive results from pivotal pharmacokinetic study of LevoCap ER

People with severe asthma are less likely to respond to treatment

Amino acid arginine improves treatment for type 2 diabetes

New drug delivery system using NDs allows for direct application of chemotherapy to brain tumors

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Amendments to oral cancer bill would increase co-pay for oral cancer treatment, says NPAF

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

D&A PHARMA to present 3 clinical studies for ALCOVER in 14th Congress of ESBRA at Warsaw

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Apoptosis can reactivate latent herpesviruses in dying cell

Rigel Cuts 30 Jobs, Refocuses On Three Clinical Programs

Survey shows most Americans are not prepared to deal with dental emergency

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Experimental agent fails to increase HDL levels, reveals new study

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News